Eurofins Agroscience Services’ Post

🚀I'm thrilled to announce that I'll be speaking at the upcoming DIA Global Meeting, taking place in San Diego, US, between 16-20 June, on a topic that's close to my heart: Digital Biomarkers as Clinical Endpoints - The Road to Regulatory Acceptability. 💡In an era where technology and healthcare are increasingly intertwined, digital biomarkers offer groundbreaking potential to revolutionize clinical trials and patient care. This session will explore how we can harness these innovative tools to meet regulatory standards and improve health outcomes worldwide. 🔍In my speech, I'll be diving deep into the current landscape of digital biomarkers, with the focus on Europe, and exploring the path towards wider regulatory acceptance. I'll be sharing real-world examples and @Bayer’s perspective to help us navigate this exciting new frontier in clinical research. 🙏I'm especially grateful to Susan Awad and Lina AlJuburi for inviting me to share the industry insights on this critical topic. Digital biomarkers have the potential to revolutionize clinical trials, offering a more objective and efficient way to measure treatment effects. However, their regulatory acceptance is still evolving. 🌐 If you're interested in the future of clinical trials and the potential of digital biomarkers, then be sure to join the conference! I look forward to a stimulating discussion and the opportunity to connect with fellow leaders in the healthcare industry. hashtag #digitalhealth hashtag #clinicaltrials hashtag #regulatoryaffairs hashtag #globalhealthcare hashtag #digitalbiomarkers hashtag #DIA2024 https://ow.ly/XxFR50QwsWt Steve Berman – BIO, Deputy Vice President, Science and Regulatory Affairs Strategy Gul Erdemli – Novartis, Global Program Regulatory director Anindita (Annie) Saha – FDA Associate Director for Strategic Initiatives, Digital Health Center of Excellence Marwan Fathallah, President and Chief Executive Officer, DIA Global Ania Mitan, DIA Susan Benedetti, MSOL, DES, Senior Project Manager, Global Annual Meeting Maureen Lamplugh, Retired, Former Annual Meeting Program Manager, DIA Christian Rommel, Bayer AG Stefan Oelrich, Bayer AG Elena Popa, Bayer AG Antoine Manson, Bayer AG

The central role of BIFIDObacteria in 'all Covid things". GI doc w/ 200 clinical trials summarizes the findings in front of the Ron Johnson committee. Very useful insigths into the viral n vaxx dynamics n how the MIC blocks true science. https://lnkd.in/dMTFQYbE

Great lecture on Lithium by Dr. Meyer!

What you see is what you get! Glad to see you in Barcelona the next days! Roche is proud to bring together industry leaders who will share the latest on Clinical Trials to RWD at the European Society for Retnal Specialist Congress. I hope to see you there! #EURETINA24 #Ophthalmology #MedicalEducation #RocheOphthalmology #EyeHealth #RealWorldData

Tomorrow at 9AM EST (15.00 CET) I will be talking about Multidimensional Thresholding (MDT) at the IAHPR seminar. This will include results from a study where we compared preference information from a discrete choice experiment (DCE) to preference information from MDT. Reed Johnson will be the discussant. Please join via this link: https://lnkd.in/ev-mM2ti. Why attend? There is an increasing push to widen the preference toolbox beyond DCEs, both from the scientific community as well as decision makers. This push is largely grounded in sample size requirements of DCEs that would potentially prevent preference research in rare or ultra rare diseases as well as small minorities. This is concerning if we think that all patient voices matter. For instance, "patient values related to rare diseases" is listed as a broadly applicable preference sensitive area by the FDA: https://lnkd.in/ef3jRdTH Advancing a novel preference instrument is exciting and lots remains to be done! Let's work on this together as one scientific community. One main motivation for me to give this seminar is to encourage you all to chip in with valuable methods work, inspiring ideas, and/or applications. Thank you IAHPR Office for the invitation!

Growing in Europe!

As healthcare marketers, understanding the evolving landscape of R&D in chronic diseases is paramount. Immunic, Inc. is set to host a Multiple Sclerosis R&D Day on September 10, featuring insights from industry leaders on innovative therapies like vidofludimus calcium. With participation in key scientific conferences throughout September, this is an opportunity to grasp emerging trends and strategic directions in MS treatment. Mark your calendars! #HealthcareMarketing #MSResearch #Immunic

Exciting week to talk about #scleroderma and rare musculoskeletal diseases. Hopefully see many of you in Prague! #clinicaltrials #imaging #cartcelltherapy #innovation #pharma #biotechnology

The placebo effect can no longer be disregarded. Acknowledging and addressing the placebo effect is crucial for the success of your clinical trials...Learn more during this webinar !

Come to join us at #EuropeanExpertPE meeting in Mainz Oct24. Highest PE experts covering a top scientific program about this life threatening disease, with an overall focus on a #multidisciplinaryapproach, ranging from diagnosis to #interventionaltherapies. At Boston Scientific we are committed to the scientific community to improve PE outcomes, so do not hesitate to contact us if you would like more information about our value proposition. #ExpertPE #PulmonaryEmbolism #CatheterDirectedTherapies #USAT